*The following content is generated by AI and is for reference only.
Repaglinide is a rapidly acting oral antidiabetic medication belonging to the meglitinide class, primarily utilized in the management of type 2 diabetes mellitus. Its chemical identity is defined by the molecular formula C24H31NO4 and the CAS registry number 150678-52-7. Structurally, it features a complex arrangement of aromatic rings and a methoxy group, which facilitates its specific interaction with pancreatic beta-cell ATP-sensitive potassium channels.
The primary clinical purpose of Repaglinide is to lower postprandial blood glucose levels in patients who have not achieved adequate glycemic control through diet and exercise alone. Unlike sulfonylureas, which have a longer duration of action, Repaglinide acts quickly after administration and has a short half-life, typically around one hour. This pharmacokinetic profile allows for flexible dosing schedules that can be adjusted based on meal patterns, making it particularly suitable for patients with irregular eating habits. The drug functions by stimulating insulin secretion from the pancreas in response to elevated blood sugar levels following food intake, thereby reducing hyperglycemia without causing prolonged hypoglycemia if meals are skipped.
Common brand names include Prandin and NovoNorm, depending on the regional market. While highly effective, Repaglinide carries risks such as hypoglycemia, weight gain, and potential gastrointestinal disturbances. It is generally contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Furthermore, caution is advised when co-administering with gemfibrozil due to significant metabolic interactions that can drastically increase plasma concentrations of the drug. Overall, Repaglinide represents a valuable therapeutic option for optimizing glycemic control in diverse type 2 diabetes populations, offering a balance between efficacy and dosing flexibility.